glp-1/gip/gcg receptor agonist Effects, working principles and target tissues of dual agonists Regulation of GLP-1 and Glucagon
Description
Although evidence from clinical trials has shown GLP-1 RAs to be safe and efficacious in people living with T2DM and renal impairment, their use is uncommon in this patient population
Once Monthly GLP-1 Maridebart cafraglutide is an investigational once-monthly injectable drug developed by Amgen that shows significant promise for treating obesity and Type 2 diabetes
Jacqueline Maya,
Genes affect how well semaglutide (Ozympic) and tirzepatide work
Compound Name: Retatrutide (Triple Agonist Analog)
